Biparametric MRI for Prostate Cancer Diagnosis Shows Promising Results

Strategic Insights -

A recent study published in JAMA compared the use of biparametric (bpMRI) and multiparametric (mpMRI) MRI for prostate cancer diagnosis. The study, led by Prof Freddie Hamdy and Prof Jenny Donovan, found that bpMRI was non-inferior to mpMRI in detecting clinically significant disease. However, the authors emphasized several limitations of the study, including the flawed definition of "clinically significant disease" and the potential for overdiagnosis. The study also highlighted the need for further investigation into the use of bpMRI in staging and planning treatment.

Key Takeaways:

  • The PRIME study showed that bpMRI was non-inferior to mpMRI in detecting clinically significant prostate cancer.
  • However, the study's authors emphasized several limitations, including the flawed definition of "clinically significant disease" and the potential for overdiagnosis.
  • The study suggested that the use of bpMRI could lead to increased cost and burden on health systems, especially if less experienced centers continue to request mpMRI.
  • The study's authors cautioned against using the results to justify the adoption of screening for prostate cancer due to the risk of overdiagnosis.
  • The study's design was pragmatic, looking at whether bpMRI was not significantly worse than mpMRI, rather than aiming to show superiority.
  • The study highlighted the potential benefits of bpMRI, including increased scanning capacity and reduced need for radiologists.
  • 78.4% of patients diagnosed with prostate cancer using bpMRI had clinically significant disease.
  • The study's authors highlighted the need for further investigation into the use of bpMRI in staging and planning treatment, particularly in centers with less expertise.
  • 34.5% of patients diagnosed with prostate cancer using mpMRI had clinically significant disease.
  • The study's design was not randomized, and the selected patient group and order of tests could introduce bias.
  • The study's authors noted that the cost and burden of repeated mpMRI scans would need to be monitored and investigated further.

Sources:

  • Ng et al. (2025). Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA. https://doi.org/10.1001/jama.2025.13722
  • Prof Freddie Hamdy and Prof Jenny Donovan (2025, September 10). Press release. University College London.